Heska (HSKA) Rating Lowered to Sell at ValuEngine

ValuEngine downgraded shares of Heska (NASDAQ:HSKA) from a hold rating to a sell rating in a report issued on Friday morning.

Other analysts also recently issued reports about the stock. B. Riley reissued a hold rating and issued a $96.50 price target on shares of Heska in a report on Friday, October 27th. BidaskClub cut shares of Heska from a hold rating to a sell rating in a research note on Saturday, December 9th. Raymond James Financial restated a buy rating on shares of Heska in a research note on Monday, December 4th. Canaccord Genuity assumed coverage on shares of Heska in a research note on Thursday, October 5th. They issued a buy rating and a $115.00 price objective for the company. Finally, Zacks Investment Research cut shares of Heska from a hold rating to a sell rating in a research note on Wednesday, January 3rd. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $110.08.

Shares of Heska (NASDAQ:HSKA) opened at $72.09 on Friday. Heska has a 1-year low of $71.03 and a 1-year high of $115.00. The firm has a market cap of $518.44, a price-to-earnings ratio of 37.47, a price-to-earnings-growth ratio of 1.88 and a beta of 0.67.

In other news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the transaction, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 14.70% of the company’s stock.

Several hedge funds have recently made changes to their positions in HSKA. Swiss National Bank acquired a new position in shares of Heska in the 2nd quarter valued at $1,082,000. Teachers Advisors LLC increased its position in shares of Heska by 7.8% during the 2nd quarter. Teachers Advisors LLC now owns 11,414 shares of the medical research company’s stock worth $1,165,000 after purchasing an additional 824 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Heska by 77.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 43,518 shares of the medical research company’s stock worth $4,442,000 after purchasing an additional 18,952 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Heska by 5.8% during the 2nd quarter. New York State Common Retirement Fund now owns 9,597 shares of the medical research company’s stock worth $980,000 after purchasing an additional 525 shares in the last quarter. Finally, D.A. Davidson & CO. increased its position in shares of Heska by 0.3% during the 2nd quarter. D.A. Davidson & CO. now owns 1,943 shares of the medical research company’s stock worth $198,000 after purchasing an additional 5 shares in the last quarter. Institutional investors own 80.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2018/02/06/heska-hska-rating-lowered-to-sell-at-valuengine.html.

Heska Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply